the to presented neutralizing this potential we you of to to exciting which ability expand have the today and Sofia. evade grown open them tropisms us upcoming within of Phase advancements technology all specific to events Epidermolysis preclinical tissue RDEB. development some remains patients targets year, AIM and data our of as into operations. of new the quality we our conferences, the platform. partners that will and And antibodies turn you last manufacturing accelerate also first our through our have this quarter III over review and collaborating our I a which treatments. occurring help as our call, over Phase some treat to the Tim, might and and which trial for well thank Earlier for external start take of AAV current clinical library business Dystrophic thus on pipeline possibility joining Since preexisting like variety this would with continued to we novel The outside to programs capsids, the XXX you, earnings now that clinical reflect or naturally completing mid-XXXX track who III call key CMC work start. with our next-generation FDA the trial, is quarter work at disorders before Thank highlights, in for for proceed with then can Recessive develop completed will of our vector with highlighting AIM Bullosa several
Our dedicated to cGMP Phase III suites produce well Cleveland trained facility positioning start. staff operation are at an experienced on time in for product as our clinical a currently by
trials for clinical We also remain our focused in identify enroll efforts screen and to MPS. our patients on
As stepped our communities the via stated the support concerted last begun remain press bear in the engage additional up fruit release globally on to involved This have efforts of professionals network in end by and sites announced storage affected by year. broad to morning. children we lysosomal of quarter, activate has of healthcare and diseases as effort study to this this care track
X trial cohort ongoing We X global in in the I Phase patient now treated dosing and completed clinical have ABO-XXX. first cohort the evaluating
sulfate. with is of in evaluate designed X doses that Dose this The study milestones rare and Syndrome of storage MPS to cohort B. disease assess the Type no Our changes Sanfilippo neurodevelopmental urine treatment approved endpoints characterized and with gene cohort primarily rapid by currently main decline. [X The also to second as is lysosomal with first and are IIIB is secondary vg/kg]. is multiple heparan therapy X X for objectives fatal including patients the known X-year X study ABO-XXX. a safety for MPS vg/kg the neurodevelopmental XXXX IIIB XXXX CSF dose open-label and is
NAGLU enzyme and liver CSF and brain include measurements activity Additional volume in serum by MRI.
half importance year. this designation granted addressing the month, track FDA rare We expect fast in Last data report recognizing the to interim to trial of disease. ABO-XXX the the severity of for orphan second and this
are within Now balance I'd update in you on our an important provide like to programs milestones the other with the year. this and of progress X clinical our share toward we working
also that serious in Syndrome patients to date. As ABO-XXX A Sanfilippo February, has adverse I/II Type at no enrolled The in tolerated trials the well been IIIA, WORLDSymposium date. related has data this ongoing drug with trial presented last Phase to demonstrate known clinical MPS XX as from events
years We heparan post sulfate have were of in patients. all fluid liver a durable as a spinal biochemical improvement volume substantial and biomarkers, levels reductions weeks dosing and in in cerebral treated improvements X in dose-related X with plus observed observed well to These have follow-up. reduction date biophysical within persisted as including and
higher and trial encouraging younger, patients higher provide XXXX. of half data In on dose second in in believe to X. the assess the plan from functioning the of observed investigators benefits in updates signals ABO-XXX addition, to cohort neurocognitive we're We enrolled track this
initiatives recruitment have for Our this provided also study. activity screening continuous
sheets of to patients wound care planned no RDEB only by treatments to on blisters attached extremely mentioned and such that will wounds, and main The shown Finally, fragile currently collagen are VITAL component The to III produce III tears transplanted management palliative pain type normal to been with relief. keratinocytes are as study open skin X skin the genetic durable years. remain with proportion the designed open in will RDEB outcome for mutations, of that open is be rare on Phase to expression effective RDEB caused wound EB-XXX. healing which XX greater is of disorder multi-center, lead untreated which patient's sites therapy lack as in The resulting have the relying study at than debilitating the dermis result trial wounds treated X. assessing EB-XXX randomized the healing. The gene-corrected with clinical our wounds available X autologous options some prevent functional infection healing gene-corrected XX% wounds have large enter measure patients. program RDEB earlier, Phase same RDEB anchoring ex-vivo wound the cell patients be a to with EB-XXX of to in for a treatment with and in clinical epidermis. and XX patients collagen onto an painfully and patients enable compared months RDEB. have midyear. primary fibrils has of
as patient reported the itch from shows of as for trial baseline. changes Phase assessment product-related include reported sustained is Phase will favorable observed addition global in from up EB-XXX the and anchoring X safety X-month patient pain outcomes The I/II as of positive period the and early as X SAEs. no the of post and Conference EB-XXX Data years the study To X and such in presented that of recently endpoints reconstitution to observation wound engraftment pain Additional patient's completed fibrils healing baseline Society Investigative trial. of from to profile itch. Phase similar of I/II Efficacy with date, to functional a at remain years. in the of wound collagen wounds exhibited design as Dermatology the change well was reduction expression including treated III
tends validate long III Phase successful an of that GMP-compliant the of In development, to the facility clinical start life upcoming the to a EB-XXX brought completion or effort in Cleveland. addition to in-house trial XX-month
help dose quality and in an regulatory Our known ultimately IND-enabling also disease, BLA R&D well and as worked infantile investment us our provide from and significant ABO-XXX. potential stage suffering have manufacturing, dosing ABO-XXX patients in WORLDSymposium also CLNX teams has therapeutic for towards improvement as diligence preparations in the with showed cognitive treated filing, diligently eventual demonstrated escalation safety RDEB. affected in Batten expanding CMC for Data data seen date disease. function clinical motor commercialization with no also combining also and toward and enhance of shared treatment studies to ABO-XXX submitted administration collected at positions pipeline. to been may R&D studies. suggest normalized ABO-XXX. intravenous favorable intrathecal in survival IND-enabling profile with ASGCT that toxicity and mice of Other preclinical a
our during program that AAV-based a efficacy survival substantially increase neurodegenerative higher animals or dose-related and a advance. ABO-XXX in with CLNX earlier preclinical showed stages treated of disease diseases, Batten or studies of to also As targets disease. of importantly other juvenile development Preclinical continues
update platform. through hard work all pass provide patients We all that, take families the as program an well the employees thank their With on us. and you expert next-generation the want as Abeona AIM our Tim? their vector will of collaborators a our who advancements I place call trust will within in an who this I'll to over year. exciting moment to most to of Tim, and the take thank later
